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The rapid spread of human immunodeficiency virus (HIV) worldwide makes it a high priority to develop an effective vaccine. Since live
attenuated or inactivated HIV is not likely to be approved as a vaccine due to safety concerns, HIV virus like particles (VLPs) offer an attractive
alternative because they are safe due to the lack of a viral genome. Although HIV VLPs have been shown to induce humoral and cellular immune
responses, it is important to understand the mechanisms by which they induce such responses and to improve their immunogenicity. We generated
HIV VLPs, and VLPs containing Flt3 ligand (FL), a dendritic cell growth factor, to target VLPs to dendritic cells, and investigated the roles of
these VLPs in the initiation of adaptive immune responses in vitro and in vivo. We found that HIV-1 VLPs induced maturation of dendritic cells
and monocyte/macrophage populations in vitro and in vivo, with enhanced expression of maturation markers and cytokines. Dendritic cells pulsed
with VLPs induced activation of splenocytes resulting in increased production of cytokines. VLPs containing FL were found to increase dendritic
cells and monocyte/macrophage populations in the spleen when administered to mice. Administration of VLPs induced acute activation of
multiple types of cells including T and B cells as indicated by enhanced expression of the early activation marker CD69 and down-regulation of
the homing receptor CD62L. VLPs containing FL were an effective form of antigen in activating immune cells via dendritic cells, and
immunization with HIV VLPs containing FL resulted in enhanced T helper type 2-like immune responses.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV; Virus-like particle; Flt3 ligand; Immune cellsIntroduction
Virus-like particles (VLPs) are an attractive and effective
type of vaccine that includes immunologically relevant
structural proteins of viruses. VLPs are safer than live
replicating vectored vaccines because of their lack of infectivity.
Previously both neutralizing antibodies and cellular immune
responses were shown to be induced by various insect cell-
produced VLPs, including HIV VLPs (Buonaguro et al., 2002,
2005; Deml et al., 1997; Notka et al., 1999), human
papillomavirus (HPV) VLPs (Harro et al., 2001), and hepatitis
type C virus VLPs (Jeong et al., 2004).
Dendritic cells (DCs) are very efficient antigen presenting
cells involved in priming naive CD4+ and CD8+ T cells, thus⁎ Corresponding authors. Fax: +1 404 727 8250.
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doi:10.1016/j.virol.2006.12.014inducing primary immune responses and permitting establish-
ment of immunological memory. Located at strategic sites in the
body where pathogens enter the organism, DCs capture and
process antigens, migrate to lymphoid organs (the spleen and
lymph nodes), and display antigens at the cell surface in the
form of peptides associated with MHC II, which stimulate
CD4 T helper (Th) cells. For induction of CD8 T cells, MHC I-
associated peptides are derived from endogenously synthesized
proteins as well as from exogenous antigens (Bachmann et al.,
1996; Reimann and Schirmbeck, 1999). Another signal
necessary to prime immune responses is the expression of co-
stimulatory molecules on antigen presenting cells such as B7
family proteins (CD80, CD86) and CD40 that are recognized by
CD28 and CD40 ligand on T cells. When activated, DCs up-
regulate MHC I and II molecules and the costimulatory
molecules CD80 and CD86, and increase the secretion of
cytokines thereby facilitating the priming of naive CD4+ T-
helper and CD8+ cytotoxic T cells.
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to their extremely small number in peripheral tissues and in
blood. Flt3 (fms-like tyrosine kinase receptor) ligand (FL) is a
hematopoietic growth factor that results in expansion of
hematopoietic progenitors in the bone marrow and spleen,
and potent mobilization of progenitor cells into the circulation.
Examination of the tissues in FL-treated mice has indicated that
FL has the unique ability to expand the number of both
lymphoid-derived (CD8α+) and myeloid-derived (CD8α−), and
Langerhans cell-derived DC subsets in several sites including
the spleen, lymph nodes, and Peyer's patches, as well as in the
circulation, lungs, and liver (Maraskovsky et al., 1997;
Pulendran et al., 1997).
VLPs are considered to be relatively less effective immuno-
gens in inducing cellular immune responses as compared to live
attenuated viruses or replicating viral vector-mediated vaccines
due to their non-replicating property. Therefore, it is highly
desirable to develop approaches to enhance the immunogenicity
of VLPs, and targeting VLP antigens to DCs could be an
approach to enhance their immunogenicity. In this study, we
investigated the initial responses of immune cells to VLPs in
vitro and in vivo, the potential of targeting HIV VLPs to DCs by
incorporation of FL into VLPs resulting in enhancement of their
immunogenicity, and the effects of VLPs on activating DC
populations and other immune cells. These studies offer insight
on understanding the onset of immune responses against
particulate VLP antigens and explore novel approaches to
develop effective vaccines based on VLPs.
Results
Production of HIV VLPs containing FL
Amembrane-anchored form of human FL was constructed to
determine whether it could be incorporated into VLPs. Using aFig. 1. DNA constructs and characterization of HIV VLPs. (A) Schematic
diagram of DNA constructs. The FL is composed of a TPA signal peptide,
extracellular domain of FL (158 aa), and HIV-1 Env TM (aa 675–703) with
some extracellular (aa 661–674) and truncated cytoplasmic tail (aa 704–721)
domains. Gp160 is a full-length of HIV-1 ConB Env (863 aa). All these
constructs were used to develop rBVs expressing FL, HIV-1 Gag, or Env gp160.
(B) Western blot analysis of sucrose gradient purified VLPs probed with patient
sera. (1) HIV VLPs (Gag+Env gp160), (2) VLPs containing FL (Gag+Env
gp160+FL). (C) Western blot analysis of sucrose gradient purified VLPs con-
taining FL probed with goat anti-FL antibody. HIV-1 and VLPs containing FL
were run on 12% gels and probed with anti-FL antibody. (1) HIV VLP (Gag+
Env gp160), (2) VLPs containing FL (Gag+Env gp160+FL). (D) Quantitative
estimation of Env in VLPs and FL-containing VLPs. ELISA plates were coated
with sheep anti-HIV-1 gp120 antibody in bicarbonate buffer (5 μg/ml). VLPs
were treated with RIPA buffer (10 μg/5 μl) and added to the ELISA plates. The
amount of HIV Env was quantitatively determined using rabbit anti-HIV-1
polyclonal sera. HIV-1 gp120 MN was obtained from the NIH AIDS Research
and Reference Reagent Program, and used as a standard. V-Gag: HIV-1 Env-
negative VLPs (Gag), V-HIV: HIV-1 VLPs (Gag+Env), V-HIV-FL: HIV VLPs
containing FL (Gag+Env+FL). (E) Quantitative estimation of FL in VLPs.
VLPs containing FL were treated with RIPA buffer (10 μg/5 μl) and were added
to the ELISA plate coated with monoclonal antibody against human FL. The
amount of human FL was determined using a standard curve obtained with the
purified FL protein.similar approach, we recently demonstrated that membrane
anchored forms of the soluble cytokine GM-CSF could be
incorporated into VLPs (Skountzou et al., in press). The human
FL-encoding gene was modified to contain the sequences
coding for the HIV transmembrane (TM) with partial
extracellular and cytoplasmic tail domains and a signal peptide
from tissue plasminogen activator (Fig. 1A). HIV gp160 is the
full-length HIV-1 Env protein (Fig. 1A). Sf9 insect cells co-
infected with rBVs expressing HIV-1 Gag, Env, or FL released
VLPs containing HIV Env (V-HIV; Gag+Env) or VLPs
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culture supernatants. The presence of HIV Env, Gag, and
human FL proteins in the purified VLPs was shown by Western
blots (Figs. 1B, C).
To characterize HIV VLPs and VLPs containing FL in detail,
it is important to determine quantitatively the amounts of
protein incorporated into VLPs. The HIV Env protein in
detergent-lysed VLP was captured onto an ELISA plate coated
with HIV Env-specific antibody, and the amount of captured
HIV Env was determined using HIV Env-specific polyclonal
anti-sera (Fig. 1D). HIV-1 Env reactivity was not found in the
Gag VLPs (V-Gag) without HIV-1 Env used as a negative
control. Similarly, antibodies specific to FL were used toFig. 2. VLPs induce in vitromaturation ofDCs. (A)Gating ofCD11c+DCpopulations.
on CD11C+ magnetic beads. (B) Flow cytometry profile of DC activation markers of p
FL plasmid DNA, purified as in panel A, and DCs (1×106/ml) were incubated with VL
vitro after staining the cells with antibodies against surface markers CD40, CD80, an
CD80, and CD86 induced by various VLPs was derived from the panel B and presendetermine FL incorporated into VLPs. HIV-1 VLPs without FL
were used as a negative control (Fig. 1E). The HIV Env protein
was found to be present at levels of 1–1.5% of total VLP protein
and the level of FL incorporated into VLPs was found to be
0.05% of the total protein content. The molar ratio of trimeric
HIV Env:FL incorporated into VLPs was estimated as
approximately 2:1.
Effects of VLPs on DC maturation and cytokine production
in vitro
Injection of mice with a plasmid DNA encoding human FL
was recently shown to expand DC populations (Nayak et al.,DCs expanded in vivo by injection ofmicewith the FL plasmidDNAwere purified
urified DC populations. DCs were obtained from spleens of mice that received the
Ps (10 μg/ml) overnight. Stimulated DCswere characterized for DCmaturation in
d CD86. (C) Mean fluorescent intensity (MFI) for DC activation markers CD40,
ted. These data are representative from three independent experiments.
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provide a useful tool to expand and isolate DCs, and to study
DC populations in vitro. The in vivo expanded DCs by FL-
encoding DNAwere used in this study (Fig. 2A). Unstimulated
DCs showed only background levels of expression of activation
markers CD40, CD80, and CD86 similar to those observed by
isotype control antibody staining. Incubation of DCs with VLPs
resulted in increases in the levels of mean fluorescence intensity
(MFI) of DCs expressing CD40, even at higher levels than those
observed with LPS stimulation (Figs. 2B, C). More prominent
increases were also observed in CD80 and CD86 expression on
DCs after incubation with VLPs as compared with CD40.
Interestingly, HIV VLPs increased the expression of CD86 on
DCs to higher levels than those observed upon treatment with
Env-negative Gag VLPs. The effects of VLPs on activating DCFig. 3. VLPs stimulate DCs to secrete cytokines. (A) Cytokine IL-12 produced
by VLP-activated DCs. (B) Cytokine IL-6 produced by VLP-activated DCs.
Purified DCs (1×106/ml) were incubated with three different concentrations of
VLPs for 24 and 48 h, culture supernatants were collected and used for the
determination of cytokines. Representative data are presented from five
independent experiments, and the values represented are mean value of
duplicate wells used in each assay. Numbers in the parentheses indicate the
amount of VLPs in μg. V-Gag: VLPs with Gag alone, V-HIV: VLPs with Gag+
Env, LPS: Lipopolysaccharide.
Fig. 4. VLP-loaded DCs induce lymphocyte proliferation. Cell proliferation of
splenocytes stimulated by VLP-loaded DCs. Total spleen cells, CD4+ and CD8+
T cells (1×105) were incubated with VLP-activated DCs (1×104) in 200 μl
media. After 6 days of incubation, cells were pulsed with [3H]-thymidine and
incorporated radioactivity was measured as an indicator of cell proliferation.
Geometric mean values are shown from triplicate wells and representative
results were from three independent experiments. Difference in CD4+
proliferation between V-HIV and V-HIV-FL is indicated, a: P=0.011.populations were observed with as low as 0.1 μg/ml concentra-
tion of VLPs. VLPs containing FL showed similar increases in
activation marker expression as compared with VLPs without
FL (data not shown).
To determine the type of responses elicited by DCs
stimulated with VLPs, the pattern of cytokine production was
determined. At concentrations over 1 μg of VLPs or after
longer incubation with VLPs (48 h), DCs were stimulated to
produce IL-12 (Fig. 3A). HIV VLPs stimulated DCs to secrete
IL-12 at higher levels than Env-negative Gag VLPs (Fig. 3A).
In contrast to IL-12, a low concentration (0.1 μg) of VLPs
stimulated DCs to secrete IL-6, and HIV VLPs induced DCs to
secrete significantly more IL-6 than Gag-VLPs (Fig. 3B).
Levels of cytokines IL-6 and IL-12 produced by DCs
stimulated with HIV VLPs were comparable to those induced
by LPS stimulation (Fig. 3). Cytokines IFN-γ, IL-10 and TNF-
α were also measured, but found to be below the detection
levels (data not shown). We did not observe any significant
differences in activation marker expression and cytokine
production between VLPs with and without FL (data not
shown). In summary, these results indicate that HIV VLPs can
induce DC maturation and stimulate them to secrete specific
cytokines, and that HIV VLPs were found to be more effective
in stimulating DCs than Gag-VLPs.
VLP-loaded DCs induce lymphocyte proliferation and cytokine
production
To investigate functional activity of VLP-loaded DCs as
antigen presenting cells, purified DCs were pulsed with VLPs
and then used to determine whether the VLP-loaded DCs could
stimulate naive splenocytes. The total splenocytes, purified
CD4+, or CD8+ T cells from naive mice were incubated with
Fig. 5. VLP-loaded DCs stimulate lymphocyte to secrete cytokine production in
vitro. The experiments were set up similar to the cell proliferation assay (see Fig.
4 legend) for total naive spleen cells and CD4+ and CD8+ cells. The culture
supernatants were used to determine the concentration of cytokines using
ELISA. (A) IL-5, (B) IL-10, and (C) IFN-γ. The values represented are mean
value of duplicate wells used in the assay and representative data are presented
from two independent experiments. Medium, DCs without VLP incubation; V-
Gag, DCs loaded with Gag VLPs; V-HIV, DCs loaded with HIV VLPs; V-HIV-
FL, DCs loaded with HIV VLPs containing FL; LPS, DCs loaded with LPS. All
values in DCs stimulated with VLPs were significantly higher than DCs without
VLPs (medium control), and V-HIV-FL values that showed statistical
significance were marked (a: P<0.005).
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was used as an indicator for lymphocyte proliferation. Purified
DCs without exposure to VLPs (medium control) showed only
background levels of spleen cell proliferation, whereas DCs
loaded with Gag VLPs or HIV VLPs induced proliferation of
spleen cells at significant levels (Fig. 4). When proliferation of
purified naive CD4+ and CD8+ T cells was determined after
incubation with VLP-loaded DCs, we observed that CD4+ T
cells proliferated at significantly higher levels compared to
CD8+ T cells. In contrast, LPS stimulated both CD4+ and CD8+
T cells. This may be due to the fact that purified populations of
CD4+ T cells have a higher number of CD4+ T cells than the
unfractionated whole spleen cell preparations. DCs exposed to
VLPs containing FL were found to be more effective in
stimulating lymphocytes, particularly in proliferating CD4+ T
cells (Fig. 4) (P=0.011 between V-HIV and V-HIV-FL). Thus,
these results indicate that VLP-loaded DCs preferentially
stimulate naive CD4+ T lymphocytes rather than naive CD8+
T cells.
The culture supernatants after incubation with VLP-loaded
DCs for 7 days were used to quantify the secreted cytokines
using ELISA. Incubation of splenocytes with purified DCs
without VLP stimulation (medium controls) did not induce
cytokine production (Fig. 5). Purified CD4+ T lymphocytes
were prominently stimulated by VLP-loaded DCs to produce
these cytokines at higher levels than unfractionated splenocytes
(Figs. 5A, B). This indicates that the enriched CD4+ T cells in
the purified CD4+ splenocytes are responsible for producing IL-
5 and IL-10 cytokines, which is consistent with the results of
proliferation (Fig. 4). The FL containing VLP-loaded DCs
resulted in production of the highest levels of IL-10 and IL-5
cytokines particularly from CD4+ T cells. In contrast to IL-10
and IL-5, splenocytes stimulated by VLP-loaded DCs secreted
IFN-γ at higher levels than fractionated CD4+ or CD8+ T
lymphocytes and there were no significant differences between
DC populations exposed to V-HIV and V-HIV-FL (Fig. 5C). In
summary, the results suggest that VLPs can be an attractive
antigenic form for uptake by DCs and that DCs pulsed with
VLPs can effectively induce naive immune cells to proliferate
and to secrete cytokines, consistent with their role as antigen
presenting cells.
Biological activity of FL in VLPs
Previous studies demonstrated that mice injected with 10 μg
of purified human FL once a day for 7 to 10 consecutive days
exhibited significantly increased CD11c+ DC populations in
peripheral tissues (Maraskovsky et al., 1996; Pulendran et al.,
1997). Using a similar protocol as described (Maraskovsky
et al., 1996; Pulendran et al., 1997) to determine the effects of
FL incorporated into VLPs (approximately equivalent to 25 ng
of FL), groups of mice were intraperitoneally (i.p.) injected with
VLPs or VLPs containing FL. Spleens collected after the day of
last injection with VLPs were found to be significantly
increased in size and in total splenocyte numbers compared to
those in naive mice (data not shown). Mice injected with VLPs
containing FL showed higher levels of CD11c+ splenocytecellularity than those injected with VLPs without FL, which was
statistically significant (Figs. 6A, B). Also, FL incorporated into
VLPs was found to increase bone marrow derived CD11c+
populations in vitro (data not shown). It is interesting to note
that mice injected with VLPs containing FL also showed
significant increases in CD11b+CD11c− monocyte/macrophage
populations compared to mice that received VLPs without FL,
which is more prominent than those of CD11c+ populations.
Thus, the results indicate that FL incorporated into VLPs
exhibits biological activity in expanding both CD11c+ and
CD11b+ populations in vivo.
Fig. 6. VLPs containing FL induced DC and monocyte/macrophage
expansion in vivo. (A) Gating of CD11c+ (DCs) and CD11b+CD11c−
(monocyte/macrophage) splenocytes. Mice (5 Balb/C mice per group) were
injected (i.p.) with 50 μg of HIV VLPs (V-HIV) or HIV VLPs containing
FL (V-HIV-FL) once a day for 9 consecutive days. On the tenth day, spleens
were collected from mice and analyzed. Spleens were processed for single
cell suspension and total cell numbers were counted after staining them with
trypan blue. One million cells were stained for mouse DC surface markers
by anti-mouse CD11b+ APC and CD11c+ FITC antibodies, and 50,000
events were acquired in Excalibur and analyzed by FlowJo software. (B)
Cellularity of CD11c+ (DC) and CD11b+CD11c− (monocyte/macrophage)
populations. The cellularity of CD11c+ and CD11b+CD11c− populations was
obtained from the total spleen cell number with percentage of DCs
calculated using Flow analysis from each mouse. The bar graph represents
the mean of total DCs in spleen of each mouse and standard deviations are
shown from five mice of each group. Statistical significances between
VLPs and VLPs containing FL are shown as follows, a: P=0.0068; b:
P=0.001. V-HIV: HIV VLPs (Gag+Env), V-HIV-FL: HIV VLPs containing
FL (Gag+Env+FL).
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For a vaccine to be effective, it should be capable of
activating various immune cell types, including DCs, B, and
T cells. To determine whether VLPs can activate immune
cells in vivo, mice were injected once with HIV VLPs, and
cellular responses to VLP administration were assessed in
splenocytes at day 3. VLP treatment induced significant
changes in the activation status of multiple cell types in the
spleen (Fig. 7). The activation markers CD80 and CD86 but
not CD40 were found to be expressed at higher levels in
CD11c+ DC populations in the VLP-administered mice
compared to those in the naive mice group (Fig. 7A). Sinceno significance differences in DC activation marker expres-
sion were found between VLPs with FL and without FL, it
seems that FL may not play a significant role in activating
DCs. This is consistent with in vitro observation as shown in
Fig. 2. When CD11b+CD11c− monocyte/macrophage popula-
tions were gated and analyzed, mice injected with FL-
containing VLPs showed moderately higher levels of CD40
and CD86 activation markers than those in mice that received
VLPs lacking FL (Fig. 7B).
The activation status of T and B cells was also examined
by analysis of the surface markers CD69 and CD62L (Rigby
and Dailey, 2000; Vilanova et al., 1996). VLP administration
induced significant increases in levels of the early activation
marker CD69 on CD4+ and CD8+ T cells, as well as B220+ B
cells compared to those in naive mice (Figs. 7C, D, E).
Administration of VLPs containing FL further enhanced
expression of CD69 on these cells. Importantly, CD62L was
significantly down-regulated on T and B cells in mice that
received VLPs containing FL. These results indicate that HIV
VLPs activate multiple cell types and that incorporation of FL
into VLPs can further enhance these effects.
Incorporation of FL into HIV VLPs enhances immune
responses to HIV Env
To investigate the immunogenicity of VLPs, mice were
subcutaneously immunized with HIV VLPs or HIV VLPs
containing FL (Fig. 8). HIV-1 Env-specific serum antibody
was determined in serum samples collected prior to
immunization and at 12 days after priming and boost
immunizations by ELISA. Immunization of mice with HIV
VLPs showed moderate levels of HIV Env-specific antibody,
which is significantly higher than those with Env-negative
Gag VLPs (V-Gag). Mice immunized with HIV VLPs
containing FL (V-HIV-FL) showed a 2-fold increase in
levels of HIV Env-specific antibodies compared to those in
HIV VLPs (V-HIV), which was statistically significant.
Since DCs exposed to the VLPs containing FL stimulated
CD4+ cells to secrete cytokines, we have determined serum
isotype antibodies specific to HIV Env. Mice immunized
with VLPs containing FL induced the highest levels of IgG1
among other isotypes (Fig. 8B), which is an indicator of T
helper type 2 responses. IgG2a isotype levels were similar to
that of VLP-immunized mice which showed a balanced level
of IgG1 and IgG2a. This result may be explained by the fact
that DCs exposed to the VLPs containing FL stimulated
CD4+ T cells to secrete IL-5 and IL-10, which are potential
T helper type 2 cytokines (Fig. 5). These results indicate
that FL incorporation into HIV VLPs can increase their
immunogenicity.
Discussion
Although DC maturation and types of immune responses
stimulated by model antigens have been studied in depth and
well-characterized (Agrawal et al., 2003; Bauer et al., 2001;
Pulendran, 2005), the mechanisms by which enveloped VLPs
Fig. 7. VLP induced activation of multiple cell types in vivo. Mice (5 Balb/C mice per group) were injected intraperitoneally with either VLPs or VLPs with FL
(V-HIV-FL) (10 μg/200 μl) on day 1 and splenocytes were isolated from each mouse at day 3 post-injection. Splenocytes were stained with antibodies for DC surface
and activation marker, T and B cell marker antibodies. The activation markers are represented as mean fluorescent intensity (MFI) of total gated cells. (A) CD11c+ DC
populations. (B) CD11c−CD11b+ monocyte/macrophage populations. (C) CD4+ T cells. (D) CD8+ T cells. (E) B220+ B cells. As determined by ANOVA tests,
statistical differences are marked between naive and V-HIV (or V-HIV-FL) groups (a: P<0.005), and between V-HIVand V-HIV-FL groups (b: P<0.05). V-HIV: HIV
VLPs (Gag+Env), V-HIV-FL: HIV VLPs containing FL (Gag+Env+FL).
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investigated the events of immune cells in response to HIV
VLPs and VLPs containing FL. HIV VLPs were found to
activate DCs in vitro resulting in enhanced expression of
maturation markers (CD40, CD80, CD86) and cytokines (IL-
6, IL-12p70). In addition, VLP-loaded DCs induced spleno-
cytes to proliferate and to secrete cytokines (IL-5, IL-10, INF-
γ). Levels of in vitro stimulation of DCs by VLPs and
activation of naive splenocytes by VLP-loaded DCs were
equivalent or higher than those induced by LPS. VLPs
containing FL were more effective in activating splenocytes
via DCs. In vivo administration of VLPs induced acute
activation of multiple types of cells including DCs, monocyte/
macrophages, and T and B cells. Incorporation of FL into
VLPs resulted in enhancement of VLP-induced activation of
T and B immune cells in vivo as indicated by increased
expression of the early activation marker CD69 and down-
regulation of homing receptor CD62L. Finally, the results
demonstrated that incorporation of FL into VLPs increased
their immunogenicity.
The in vitro and in vivo effects of HIV VLPs on immune
cells have not been previously investigated. Injection of FL-
encoding DNA resulted in a large expansion of CD11c+ DC
populations, which was found to be useful for the study of
VLP effects on DCs. Characterization of these populations
indicates that FL-DNA expanded CD11c+ populations are in
an immature state as determined by activation markers CD40,
CD80, and CD86. This is consistent with the results that FL
incorporated into VLPs did not result in significant
differences in DC activation marker expression levels in
vivo as shown in Fig. 7A and in vitro (data not shown).These results suggest that the activation of DCs observed in
this study is mainly due to the particulate nature of VLPs. FL
incorporated into VLPs may play a role for inducing DCs for
better antigen presentation as indicated by activation of T and B
cells. Incubation of the DCs with VLPs induced maturation as
shown by expression of these activation markers even at higher
levels than those induced by LPS, which suggests that VLPs can
be a strong stimulator for DCs, an important antigen presenting
cell. It is interesting to note that HIV Env-containing VLPs were
more effective in inducing maturation of DC populations than
Env-negative Gag VLPs, indicating possible additional inter-
actions between HIV Env on VLPs and an unknown receptor(s)
expressed on DCs.
The types of cytokines produced by DCs play a critical
role in determining the resulting adaptive immune responses.
We have found that HIV VLPs are efficient in stimulating
DCs to secrete Th1 type cytokine IL-12p70. A 70-kDa
heterodimeric cytokine IL-12 is the key factor that drives the
differentiation of naive T lymphocytes to Th1 cells
(Pulendran, 2004). It is an interesting finding in this study
that DCs exposed to VLPs secreted IL-6 at high levels. This
is consistent with previous studies demonstrating that murine
DCs exposed to HPV VLPs (Lenz et al., 2001) or human
blood DCs to HIV-1 (Ghanekar et al., 1996) produced IL-6 at
higher levels than other cytokines. IL-6 is a multifunctional
cytokine involved in immunity and hemopoiesis, and IL-6
was demonstrated to skew the differentiation of monocytes to
macrophages (Chomarat et al., 2000), which may explain our
result that HIV VLPs containing FL showed more significant
increases in the CD11b+ monocyte/macrophage populations
than CD11c+ DCs.
Fig. 8. Immunogenicity of HIV VLPs. (A) Total IgG specific to HIV Env. Mice
were subcutaneously immunized (5 Balb/C mice per group) with VLPs or HIV
VLPs containing FL (at weeks 0 and 4) to assess the immune responses. At
12 days after each immunization, blood samples were collected and then used to
determine HIV-1 Env-specific antibody responses by ELISA as described in
Materials and methods. Individual serum samples were serially diluted and were
run in duplicates. Purified mouse IgG was used as a standard to calculate Env-
specific antibody IgG concentrations. ANOVA tests confirmed the following
statistical differences between V-Gag and V-HIV groups (a: P=0.0071), and
between V-HIV and V-HIV-FL (b: P=0.024). (B) Isotype antibodies specific to
HIV Env. Serum samples after the first boost were diluted to 200×, added to the
ELISA plate coated with HIV Env, and levels of isotypes were determined using
the HRP-conjugated isotype-specific antibodies. Statistical difference in IgG1 is
marked between V-HIV and V-HIV-FL (a: P=0.02).
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stimulating naive immune cells as potent antigen presenting
cells. We found that DCs exposed to HIV VLPs matured to fully
functional antigen presenting cells capable of inducing naive
splenocytes to proliferate and to secrete cytokines. VLP-loaded
DCs preferentially activated naive CD4+ T cells as determined
by proliferation and production of cytokines IL-10 and IL-5, at
levels comparable to those induced by LPS stimulation. In mice,
IL-10 has been considered to be both a regulatory cytokine as
well as a Th2 inducing cytokine (Laouini et al., 2003). The
pattern of cytokine secretion from naive splenocytes stimulated
by DCs pulsed with HIV VLPs seems to induce Th2 type
responses without much CD8+ T cell activation. This is
consistent with a previous study that DCs are prone to primealloreactive CD4+ T lymphocytes toward Th 2 type cytokines
(IL-5, IL-10) in the absence of CD8+ T cell activation, which is
independent of IFN-γ production (Foucras et al., 2000). We
observed that IFN-γ was produced by whole splenocytes from
naive mice but not by CD4+ or CD8+ T cells after stimulation
with DCs loaded with HIV VLPs, indicating that other cell
types or cross talk between CD4 and CD8 T cells in naive
splenocytes might be responsible for IFN-γ production when
incubated with VLP-loaded DCs.
We observed that IFN-γ was produced by whole splenocytes
but not by CD4+ or CD8+ T cells after stimulation with DCs
loaded with HIV VLPs, indicating that non-CD4/8 T cells in
naive splenocytes were responsible for IFN-γ production when
incubated with VLP-loaded DCs. A likely candidate cell type to
be involved would be the natural killer (NK) cell. Although the
main function of DCs is the priming of naive T cells, DCs have
also been demonstrated to affect the functions of NK cells.
Human DCs were found to be capable of stimulating NK cells
resulting in IFN-γ secretion (Fernandez et al., 1999). Thus, the
reciprocal interactions between DCs and NK cells induced
during microbial infections promote rapid innate immune
responses as well as favor the generation of appropriate
adaptive responses against pathogens. However, further studies
are needed to determine whether VLP-loaded DCs can activate
NK cells to secrete IFN-γ.
Interestingly, we found that CD11b+ monocyte/macrophage
populations in spleens were significantly increased by HIV VLP
treatment and that FL-containing VLPs further increased these
populations. We also observed that a single dose of VLPs
induced significant changes in the activation status of DCs and
monocyte/macrophages as indicated by increased expression of
activation markers CD80 and CD86, which implies that VLP
antigens are effective stimulators for activation of DC and
macrophages in vivo. These changes in DC/macrophage
activation status induced by VLPs are likely to be efficient at
alerting adaptive immune responses resulting in activation of T
and B cells. Analysis of splenocytes after VLP administration
showed that significant enhancement in expression of the early
activation marker CD69 was observed in multiple cell types of
the adaptive immune system including CD4+ and CD8+ T, and
B cells. The level of CD69 was significantly higher in mice that
received VLPs containing FL than that in mice that received
VLPs without FL. After successful antigen encounter, the
responding lymphocytes down-regulate CD62L, the lymph
node homing receptor (Rigby and Dailey, 2000). Consistent
with these previous studies, analysis of splenocytes from mice
that received FL-containing VLPs showed a significant down-
regulation in CD62L expression on CD4+ T and CD8+ T cells
and B cells, indicating that these lymphocytes encountered
antigens as a result of VLP administration.
In summary the present study has shown, for the first time,
that HIV VLPs and VLPs containing FL can expand DCs and
monocyte/macrophage populations. HIV VLPs induced the
early maturation of DC populations resulting in activation of
multiple cell types both in vitro and in vivo. DCs pulsed with
VLPs induce activation of CD4+ T cells preferentially, and
VLPs containing FL were found to be a more effective form for
339G. Sailaja et al. / Virology 362 (2007) 331–341activating immune cells via DCs. Finally, FL-VLPs were found
to be a more effective immunogen in enhancing immune
responses to VLPs when mice were immunized. The results
obtained in this study provide insight in understanding VLP-
induced early events of immune responses.
Materials and methods
Cells and DNA constructs
Spodoptera frugiperda Sf9 cells were maintained in suspen-
sion in serum free SF900II medium (GIBCO-BRL) at 27 °C.
Codon optimized consensus B (ConB) sequences for Gag and
Env genes of HIV-1 were described (Kothe et al., in press) and
obtained from Dr. Beatrice Hahn (University of Alabama at
Birmingham). ConB genes encoding HIV-1 Gag and Env were
cloned into the pc/pS1 transfer vector under the hybrid capsid-
polyhedrin promoter, and recombinant baculoviruses (rBV)
expressing HIV-1 ConB Gag or Env were constructed as
described previously (Yamshchikov et al., 1995; Yao et al.,
2000). A plasmid pNGVL3-hFLex containing a gene encoding
human FL with a signal peptide of tissue plasminogen activator
(TPA) was kindly provided by Dr. Abdul M. Jabbar (Emory
Vaccine Center). For incorporation of FL into HIV VLPs, the
extracellular domains of the human FL gene were PCR-
amplified using the forward primer, 5′-CAGTCCCCCGGGTC-
GACGCCGCCACCATG-3′ and the reverse primer, 5′-
CAGAGGGATATCCGGGGCTGT CGGGGC-3′. The PCR
product of the TPA-FL encoding gene was digested with
EcoRVand in-frame ligated to the transmembrane (TM) domain
with a small portion of the extracellular domain and truncated
cytoplasmic tail of HIV Env (aa 661–721), and cloned into the
baculovirus transfer vector pc/pS1, which was subsequently
used to generate an rBV expressing human FL in a membrane-
anchored form.
Production of HIV VLPs and VLPs containing FL
VLPs were produced from Sf9 insect cells co-infected with
rBVs expressing Gag at an MOI (multiplicity of infection) of 2
and rBVs expressing HIV Env at an MOI of 4. Gag VLPs were
produced in insect cells infected with rBVexpressing Gag alone
without co-infection with rBVs expressing HIV Env. HIV VLPs
containing FL were produced by coinfecting Sf9 cells with
rBVs expressing HIV Gag, HIV Env, and FL at MOI ratios of
2:4:4, respectively. After 60 h of culture, VLPs in the
supernatants were precipitated by adding polyethylene glycol
6000 (7%) and NaCl (2.3%), collected by centrifugation
(2000 rpm), and purified by sucrose step gradients as described
previously (Yao et al., 2000). Purified VLPs and VLPs
containing FL were analyzed on 8% SDS-PAGE gels, Western
blotted, and probed with HIV patient sera. For analysis of FL,
biotinylated goat anti-human FL (R&D systems) and HRP-
conjugated streptavidin were used to probe the membrane blot.
Endotoxin analysis using the Limulus Amebocyte Lysate test
(BioWhittaker Inc, Walkersville, MD) indicated that VLP
preparations were endotoxin-free.Quantitative estimation of Env and FL on VLPs
ELISA plates were coated with sheep anti-HIV-1 gp120
antibody (5 μg/ml) (CLINIQA, Fallbrook, CA) and monoclonal
anti-human FL antibody (R&D systems) for determining
concentrations of HIV Env and FL, respectively. VLPs and
VLPs containing FL were lysed and added to plates in serial
dilutions. To determine the amounts of captured HIV Env and
FL antigens, rabbit anti-HIV Env sera (1:1000) and biotinylated
anti-human FL antibody (R&D systems) were added and
incubated for 1 h at 37 °C. After incubation with appropriate
HRP-conjugated secondary antibodies or streptavidin, plates
were developed with TMB ELISA substrate (PIERCE) and OD
values were read at 450 nm. HIV-1 gp120 MN and human FL
(R and D systems) were used as standards to calculate the
amount of gp120 and hFL incorporated in VLPs, respectively.
DC expansion in vivo
In vivo expansion of DCs in BALB/c mice was carried out by
injecting plasmid DNA that expresses the human FL extra-
cellular domain as described by Sailaja et al. (2003). After
9 days, spleens were collected from mice that received FL DNA
and single cell suspensions were prepared after treatments with
type IV collagenase (Worthington) and lysis of red blood cells.
Single cell suspensions were incubated with CD11c (N418)
microbeads and CD11c+ DC cells were obtained by passing
through magnetic columns according to the manufacturer's
instructions (Miltenyi Biotec Inc. Auburn, CA).
VLP-induced activation of DCs in vitro
To study the effects of VLPs on DC activation in vitro, DCs
(1×106) were incubated with VLPs overnight. The cells were
harvested, washed, and stained for DC surface markers APC-
conjugated anti-CD11b and FITC-conjugated anti-CD11c
antibodies, and DC activation markers CD40, CD80, CD86,
and MHCII coupled to PE for 20 min on ice, in the presence of
an Fc receptor blocking antibody. Cells were then washed and
fixed with 1.5% paraformaldehyde and acquired in FACS
Excalibur. The results were analyzed using FlowJo software. To
determine VLP-induced cytokine secretion in DCs in vitro,
culture supernatants were used to quantify the cytokines
secreted by DCs after incubation with VLPs for 24 h or 48 h
at 37 °C. The cytokines, IL-6, IL-10, TNF-α, IFN-γ, and IL-
12p70 were assayed using ELISA kits according to the
manufacturer's instructions (eBioscience).
In vitro functional assay of VLP-loaded DC
Mouse DCs purified as described above were incubated with
VLPs or VLPs containing FL (10 μg/ml) for 6 h. DCs loaded
with VLPs were washed and counted. Spleens were isolated
from naive BALB/c mice (6 weeks old) and single cell
suspensions were prepared. CD4+ and CD8+ cells were isolated
from spleen cells using a CD4+ and CD8+ isolation kit
according to the manufacturer's instructions (Miltenyi Biotec
340 G. Sailaja et al. / Virology 362 (2007) 331–341Inc). Splenocytes, CD4+, and CD8+ T cells (1×105) were
incubated in triplicate with VLP-loaded DCs (1×104) at a ratio
of 1:10 at 37 °C for 6 days. Cultures were pulsed with 1.0 μCi
[3H]thymidine for 12 h and 3H-incorporation was measured by
β-scintillation spectroscopy. The culture supernatants were
assayed for cytokines IL-4, IL-5, IL-6, IL-10, and IFN-γ using
cytokine ELISA kits according to the manufacturer's instruc-
tions (eBioscience).
In vivo biological function assay of FL incorporated into VLP
VLPs or VLPs containing FL (50 μg/200 μl) were intra-
peritoneally (i.p.) injected into mice (5/group) daily for 9 days
as described previously for purified human FL (Maraskovsky
et al., 1996; Pulendran et al., 1997). On the 10th day, spleens
were obtained from mice, single cell suspensions were prepared
and analyzed for cellularity and DC expansion. 1×106 spleen
cells were stained with mouse anti-CD11b coupled to APC,
anti-CD11c coupled to FITC for 20 min on ice, in the presence
of an Fc receptor blocking antibody. Cells were then washed,
fixed with 1.5% paraformaldehyde, acquired using FACSCa-
libur, and analyzed by FlowJo software.
VLP-induced activation of multiple cell types in vivo
VLPs and VLPs containing FL (10 μg/200 μl) were injected
into mice (5/group) intraperitoneally (i.p.). On day 3, mice
were sacrificed and spleens were isolated and single cell
suspensions were prepared. The splenocytes were stained for
DC surface markers using mouse anti-CD11c+ coupled to
FITC, and anti-CD11b+ coupled to APC, and DC activation
markers anti-CD40 or CD80 or CD86 coupled to PE. One
million cells were stained with antibodies for CD4, CD8 T
cells, and B cells with surface markers mouse anti-CD4
coupled to PE, anti-CD8 coupled to APC, anti-B220 coupled to
PerCP, and early activation markers anti-CD69 and anti-CD
62L coupled to FITC. After staining, the cells were acquired in
Excalibur and analyzed by Flow Jo software as described
above.
Analysis of immune responses after immunizations of mice
BALB/c mice (5/group) were subcutaneously immunized
with 50 μg of VLPs or VLPs containing FL to assess the
immune responses. At 4 weeks after priming, these mice were
boosted similarly with VLPs or FL-containing VLPs. At
12 days after each immunization, blood samples were drawn
from the retroorbital plexus and serum was separated. The
serum was used to determine Env-specific antibody titer by
ELISA. HIV-ConB Env used for coating the ELISA plate was
expressed in recombinant vaccinia virus and purified using a
lectin affinity column as described (Kang and Compans, 2003;
Kang et al., 2003). After blocking, diluted mouse serum before
and after immunization was added to the HIV Env-coated plate.
Purified mouse IgG was used as standard. The plates were
developed using anti-mouse IgG, IgG1, IgG2a, IgG2b, and
IgG3 coupled to HRP (Southern Biotechnology Associates. Inc)and TMB ELISA substrate (PIERCE) and absorbance was
measured at 450 nm.
Statistical analysis
The significance of differences between groups in DC
expansion and multiple cell activation and proliferation was
determined between two groups by Student's t-test and an
ANOVA test was performed for multiple comparisons. A value
of P<0.05 was considered significant.
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